NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, January 24th. Investors of record on Friday, February 14th will be paid a dividend of $0.74 per share on Friday, March 13th. This represents a $2.96 annualized dividend and a yield of 1.53%. The ex-dividend date is Thursday, February 13th. View Allergan's Dividend History.

Allergan announced that its Board of Directors has approved a stock repurchase plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.

Allergan plc (NYSE:AGN) posted its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.57 by $0.65. The company had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.09 billion. Allergan had a positive return on equity of 9.82% and a negative net margin of 32.76%. The business's revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.29 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Allergan.

19 brokers have issued twelve-month target prices for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's stock price to reach $178.72 in the next year. This suggests that the stock has a possible downside of 7.5%. View Analyst Price Targets for Allergan.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News coverage about AGN stock has been trending somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Allergan.

Allergan saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 13,700,000 shares, a decrease of 11.0% from the January 30th total of 15,400,000 shares. Based on an average trading volume of 2,390,000 shares, the short-interest ratio is presently 5.7 days. Currently, 4.2% of the company's shares are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.39%), Franklin Resources Inc. (2.24%), Longview Partners Guernsey LTD (2.10%), Renaissance Technologies LLC (1.53%), Geode Capital Management LLC (1.45%) and Bank of New York Mellon Corp (0.77%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Assenagon Asset Management S.A., Fred Alger Management LLC, MUFG Securities EMEA plc, State Street Corp, Janus Henderson Group PLC, FMR LLC and Fir Tree Capital Management LP. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Segantii Capital Management Ltd, Bank of Montreal Can, Beryl Capital Management LLC, Laurion Capital Management LP, FIL Ltd and Vivaldi Asset Management LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $193.19.

Allergan has a market capitalization of $63.56 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]